The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

There’s really no ignoring the inexorable math that led the Senate to approve a plan that will give Medicare unprecedented power to set the prices of some drugs.

By the 1990s, a course of a breakthrough cancer drug like Taxol might already cost about $10,000 in inflation-adjusted dollars. By the early 2000s, Gleevec, one of the most potent cancer medicines ever, would be about $30,000. By 2006, to prevent public outcry, Genentech capped the cost of Avastin, its lung cancer medicine, at about $75,000 in today’s dollars. These days, a medication like Keytruda can cost $150,000 per course.

The average launch price of a cancer drug increased by $8,500 from 1995 to 2013. The Government Accountability Office found in 2021 that the prices for new medicines were double to quadruple the levels seen in France, Australia, or Canada.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In